Articles

Low inflation doesn’t help Americans if they still can’t afford to buy things

High prices persist — making life less affordable — and further increases are on the horizon

New York Giants QB Jameis Winston says he regrets letting his friends and family spend $400,000 a month of his money

Winston said he was “naive” as a young athlete coming into the NFL making $25 million.

Thank heavens for Fed Chair Jerome Powell

The latest jobs shock shows he’s been right all along.

Why Trump’s plan to lower beef, coffee and banana prices may not help Americans where they’re hurting the most

Food prices matter deeply for consumers’ wallets and their mood, economists say. Yet the expenses that are really gnawing at household budgets are far from the supermarket.

America’s ‘sugar daddy’ just went broke — and you’re stuck with the bill

Japan can’t — and won’t — finance the U.S. anymore. Here’s why that matters for your money, your mortgage and basic portfolio moves.

From price cuts to bidding wars, America’s home buyers are in two wildly different worlds

As home sales slowly recover, the Northeast and Midwest are seeing a bigger rebound than the South and the West, according to new data.

‘There’s definitely a bubble in markets,’ Ray Dalio says. But that doesn’t mean you should sell.

The situation today is not quite the same as the dot-com bubble, but the market is about 80% of the way there, says the founder of hedge fund Bridgewater Associates.

Buses are having a moment as more Americans ditch planes this Thanksgiving

Greyhound’s parent company says its passenger counts are up 17% going into the holiday.

The five biggest Nvidia highlights that are helping soothe the stock market

Nvidia delivered a big beat, posted strong networking growth and indicated a lot of visibility into future business trends.

AMD’s stock looks like a winner after Nvidia earnings. These other AI plays do too.

Nvidia’s third-quarter earnings beat alleviated AI bubble fears and sent tech shares rising across the market.

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.

This sleeper AI risk for stocks in 2026 has got Wall Street talking over the past few weeks

A slowdown in corporate buybacks as AI players add debt could steal an important source of demand from the market.
1 3 4 5 6 7 2,445